Forums
New posts
Forum list
Search forums
What's new
New posts
New resources
Latest activity
Trending Threads
Resources
Latest reviews
Search resources
FarmTV
Farm Compare
Search
Tokens/Searches
Calendar
Upcoming Events
Members
Registered members
Current visitors
New Resources
New posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Forum list
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Farm Business
Agricultural Matters
Ivermectin , covid cure
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="ollie989898" data-source="post: 7872079" data-attributes="member: 54866"><p>[URL unfurl="true"]https://kpkesihatan.com/2021/11/03/kenyataan-akhbar-kpk-3-november-2021-hasil-dapatan-kajian-keberkesanan-rawatan-ivermectin-untuk-pesakit-covid-19-berisiko-tinggi-i-tech-study/[/URL]</p><p></p><p><strong>MEDIA STATEMENT</strong> <strong>MINISTRY OF HEALTH MALAYSIA</strong></p><p><strong></strong></p><p><strong>IVERMECTIN TREATMENT EFFICACY IN COVID-19 HIGH RISK PATIENT (I-TECH STUDY)</strong></p><p></p><p><em>...The Institute for Clinical Research (ICR) NIH today announced findings for the Ivermectin study (I-TECH) in 500 hospitalised patients with Stage 2 or 3 COVID-19. This multi-centre open-label randomised controlled trial evaluated a 5-day course of ivermectin (0.4mg/kg/day) plus standard of care (IVM group), compared to standard of care (SOC group) according to Ministry of Health Malaysia (MOH) guidelines for COVID-19 patients at 20 government hospitals and MAEPS 2.0 Quarantine and COVID-19 Treatment Centre (PKRC).</em></p><p><em></em></p><p><em>The trial was conducted by infectious disease physicians and clinicians who were actively involved in COVID-19 management in collaboration with the Institute for Clinical Research (ICR), National Institute of Health (NIH). The main outcome of the I-TECH study was to see if ivermectin administered during the first week of illness prevented deterioration to severe COVID-19 Stage 4 or 5 among hospitalised patients aged 50 years and above with at least one comorbidity.</em></p><p><em></em></p><p><em>ICR Director, Dr Kalaiarasu M. Peariasamy, said the I-TECH findings showed that patients in the IVM group compared to SOC group had similar rates of progression to severe COVID-19 disease at 21.2 percent and 17.3 percent respectively (OR 1.29 [95% CI 0.82-2.02]; p = 0.30). For the same primary outcome, the mean time to progression was 3.0 days for the IVM group compared to 2.9 days for the SOC group, but the difference was not statistically significant; p=0.68.</em></p><p><em></em></p><p><em>This MOH initiated study obtained Medical Research and Ethics Committee (MREC) approval on 25th May 2021. In order to disclose to the public key information about the I-TECH study, the trial was registered in ClinicalTrials.gov on 31st May 2021 (NCT04920942). From the sample of 500 subjects enrolled in the trial, four (4) were excluded for not meeting study criteria and six (6) withdrew after expressing concerns about ivermectin side effects. The last subject was recruited on 9th October and the follow-up ended on 25th October 2021...</em></p><p></p><p>ITECH trial finds no benefit from ivermectin vs standard of care. High power study with a snitch under 500 participants. Trial doesn't seem to have appeared in any journal as yet though so not sure about it's reliability. Lots of adverse events reported in the ivermectin arm, too.</p></blockquote><p></p>
[QUOTE="ollie989898, post: 7872079, member: 54866"] [URL unfurl="true"]https://kpkesihatan.com/2021/11/03/kenyataan-akhbar-kpk-3-november-2021-hasil-dapatan-kajian-keberkesanan-rawatan-ivermectin-untuk-pesakit-covid-19-berisiko-tinggi-i-tech-study/[/URL] [B]MEDIA STATEMENT[/B] [B]MINISTRY OF HEALTH MALAYSIA IVERMECTIN TREATMENT EFFICACY IN COVID-19 HIGH RISK PATIENT (I-TECH STUDY)[/B] [I]...The Institute for Clinical Research (ICR) NIH today announced findings for the Ivermectin study (I-TECH) in 500 hospitalised patients with Stage 2 or 3 COVID-19. This multi-centre open-label randomised controlled trial evaluated a 5-day course of ivermectin (0.4mg/kg/day) plus standard of care (IVM group), compared to standard of care (SOC group) according to Ministry of Health Malaysia (MOH) guidelines for COVID-19 patients at 20 government hospitals and MAEPS 2.0 Quarantine and COVID-19 Treatment Centre (PKRC). The trial was conducted by infectious disease physicians and clinicians who were actively involved in COVID-19 management in collaboration with the Institute for Clinical Research (ICR), National Institute of Health (NIH). The main outcome of the I-TECH study was to see if ivermectin administered during the first week of illness prevented deterioration to severe COVID-19 Stage 4 or 5 among hospitalised patients aged 50 years and above with at least one comorbidity. ICR Director, Dr Kalaiarasu M. Peariasamy, said the I-TECH findings showed that patients in the IVM group compared to SOC group had similar rates of progression to severe COVID-19 disease at 21.2 percent and 17.3 percent respectively (OR 1.29 [95% CI 0.82-2.02]; p = 0.30). For the same primary outcome, the mean time to progression was 3.0 days for the IVM group compared to 2.9 days for the SOC group, but the difference was not statistically significant; p=0.68. This MOH initiated study obtained Medical Research and Ethics Committee (MREC) approval on 25th May 2021. In order to disclose to the public key information about the I-TECH study, the trial was registered in ClinicalTrials.gov on 31st May 2021 (NCT04920942). From the sample of 500 subjects enrolled in the trial, four (4) were excluded for not meeting study criteria and six (6) withdrew after expressing concerns about ivermectin side effects. The last subject was recruited on 9th October and the follow-up ended on 25th October 2021...[/I] ITECH trial finds no benefit from ivermectin vs standard of care. High power study with a snitch under 500 participants. Trial doesn't seem to have appeared in any journal as yet though so not sure about it's reliability. Lots of adverse events reported in the ivermectin arm, too. [/QUOTE]
Insert quotes…
Verification
Post reply
Forums
Farm Business
Agricultural Matters
Ivermectin , covid cure
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top